Pulmovant's mosliciguat hits primary endpoint in PH-ILD phase 2 trial

September 8, 2026 6:00 AM

Pulmovant, a subsidiary of Roivant Sciences (NASDAQ: ROIV), announced positive results from its Phase 2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found